Source:http://linkedlifedata.com/resource/pubmed/id/11035437
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
8
|
| pubmed:dateCreated |
2000-11-28
|
| pubmed:abstractText |
To improve monitoring of immunological and disease activity, we determined soluble markers of activity of the monocyte/macrophage system (sCD14) and the vascular endothelium (sE-selectin, sICAM-1) in patients with systemic lupus erythematosus (SLE) and primary Sjögren's syndrome (pSS) in comparison to patients with infections or sepsis. Concentrations of sCD14, sICAM-1 and sE-selectin (soluble CD14, ICAM-1 and E-selectin, respectively) were measured in serum samples from patients with SLE and pSS, patients with sepsis, different infectious diseases and healthy controls using ELISA systems. Elevated levels of sE-selectin and sICAM-1 were detected in patients with SLE as well as sepsis, in contrast to patients with a localized infection (SLE and sepsis, respectively, versus infection P<0.001; Kruskal-Wallis test). Levels of sCD14 were persistently elevated in sera from patients with SLE, whereas these values decreased rapidly after effective therapy in patients with sepsis or infection. A continuous elevation of all of these three parameters was associated with a fatal outcome in patients with sepsis as well as in patients with SLE. Combined elevation of sCD14, sICAM-1 and sE-selectin correlates with the prognosis in patients with active SLE and indicates a remarkable immune activation involving the monocyte/macrophage system and the endothelium comparable to an activation found only in patients with sepsis.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:issn |
0961-2033
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
9
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
614-21
|
| pubmed:dateRevised |
2006-11-15
|
| pubmed:meshHeading |
pubmed-meshheading:11035437-Adolescent,
pubmed-meshheading:11035437-Adult,
pubmed-meshheading:11035437-Aged,
pubmed-meshheading:11035437-Antigens, CD14,
pubmed-meshheading:11035437-Bacterial Infections,
pubmed-meshheading:11035437-Candidiasis,
pubmed-meshheading:11035437-E-Selectin,
pubmed-meshheading:11035437-Enzyme-Linked Immunosorbent Assay,
pubmed-meshheading:11035437-Female,
pubmed-meshheading:11035437-Humans,
pubmed-meshheading:11035437-Intercellular Adhesion Molecule-1,
pubmed-meshheading:11035437-Lupus Erythematosus, Systemic,
pubmed-meshheading:11035437-Male,
pubmed-meshheading:11035437-Middle Aged,
pubmed-meshheading:11035437-Predictive Value of Tests,
pubmed-meshheading:11035437-Prognosis,
pubmed-meshheading:11035437-Sepsis,
pubmed-meshheading:11035437-Sjogren's Syndrome
|
| pubmed:year |
2000
|
| pubmed:articleTitle |
Increased serum soluble CD14, ICAM-1 and E-selectin correlate with disease activity and prognosis in systemic lupus erythematosus.
|
| pubmed:affiliation |
Department of Rheumatology and Clinical Immunology, Charité University Hospital, Humboldt University of Berlin, Berlin, Germany.
|
| pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|